1. The sympathetic and parasympathetic divisions differ fundamentally in the relative length of their preganglionic and postganglionic fibers, and in the degree of divergence in their ganglionic architecture. Which of the following most accurately describes this distinction and explains its physiological consequence?

• A) Both divisions have equally long preganglionic fibers and short postganglionic fibers -- the physiological difference between mass sympathetic activation and discrete parasympathetic responses arises entirely from receptor subtype expression at the effector organ rather than from ganglionic architecture; a drug targeting ganglionic transmission would therefore produce identical systemic profiles for both divisions.
• B) The sympathetic division has short preganglionic fibers synapsing in paravertebral or prevertebral ganglia close to the spinal cord, followed by long postganglionic fibers reaching distant effector organs; each preganglionic sympathetic neuron synapses on an average of 20-30 postganglionic neurons (high divergence), enabling coordinated mass activation of multiple effector organs simultaneously during the fight-or-flight response; the parasympathetic division has long preganglionic fibers traveling to terminal ganglia located at or within the target organ wall, with correspondingly short postganglionic fibers and low divergence -- producing discrete, organ-specific responses rather than diffuse mass activation.
• C) The sympathetic division has long preganglionic fibers reaching terminal ganglia within target organ walls, with short postganglionic fibers and high divergence producing diffuse simultaneous activation of multiple organs including the heart, adrenal medulla, and peripheral vasculature during sympathetic arousal; the parasympathetic division has short preganglionic fibers synapsing in paravertebral ganglia, with long postganglionic fibers reaching individual organs selectively.
• D) Both divisions have short preganglionic fibers and long postganglionic fibers -- the sympathetic division produces diffuse activation because its postganglionic fibers branch extensively after leaving the ganglion to reach multiple effector organs, while parasympathetic fibers travel in unbranched single-organ pathways; ganglionic architecture is identical for both divisions and does not contribute to the difference in their physiological activation patterns.
• E) The parasympathetic division has short preganglionic fibers and long postganglionic fibers, while the sympathetic division has long preganglionic fibers and short postganglionic fibers -- the high divergence of the sympathetic preganglionic fibers enables simultaneous innervation of multiple distant organ systems; the parasympathetic division's low divergence restricts its activation to single discrete target organs near the terminal ganglion.

2. The adrenal medulla is often described as a modified sympathetic ganglion. Which of the following most accurately explains the pharmacological basis for this designation and its implications for drug therapy?

• A) The adrenal medulla synthesizes aldosterone in response to direct sympathetic nerve stimulation via alpha-1 adrenergic receptors on zona glomerulosa cells -- this links the sympathetic nervous system to mineralocorticoid-mediated sodium retention, and explains why alpha-1 blockers reduce blood pressure through both direct vasodilation and indirect reduction of aldosterone-mediated volume retention.
• B) Adrenal chromaffin cells are derived from the same neural crest lineage as parasympathetic postganglionic neurons -- they receive vagal preganglionic innervation, synthesize primarily acetylcholine and vasoactive intestinal peptide, and release these substances into the portal circulation during rest and digestion to coordinate parasympathetic organ responses systemically.
• C) The adrenal medulla receives direct preganglionic cholinergic innervation from the splanchnic nerves (originating at T5-T9) without interposing a postganglionic neuron -- adrenal chromaffin cells are embryologically derived from the same neural crest lineage as sympathetic postganglionic neurons and function as modified postganglionic neurons that have lost their axons; acetylcholine from preganglionic fibers activates nicotinic receptors on chromaffin cells, triggering release of epinephrine (approximately 80%) and norepinephrine (approximately 20%) directly into the systemic circulation as hormones rather than as neurotransmitters at a synaptic cleft.
• D) Adrenal chromaffin cells are derived from the same neural crest lineage as sympathetic preganglionic neurons -- they receive postganglionic adrenergic innervation and respond to norepinephrine by releasing epinephrine through a beta-1-receptor-mediated second-messenger cascade; drugs that block beta-1 receptors therefore reduce adrenomedullary epinephrine secretion in addition to their cardiac effects.
• E) The adrenal medulla is innervated by somatic motor fibers from the phrenic nerve (C3-C5), which directly trigger chromaffin cell secretion during inspiratory effort -- this somatic innervation explains why adrenomedullary catecholamine release is increased during exercise and respiratory distress and provides the mechanistic link between respiratory mechanics and the cardiovascular stress response.

3. The rostral ventrolateral medulla (RVLM) is described as the sympathetic vasomotor center and provides tonic excitatory drive to sympathetic preganglionic neurons. Which centrally acting antihypertensive drugs reduce this tonic drive, through what receptor mechanism, and why do they produce broader autonomic effects than peripheral antihypertensives?

• A) Prazosin and doxazosin reduce RVLM tonic drive by blocking alpha-1 adrenergic receptors within the RVLM itself, directly silencing the vasomotor neurons that provide excitatory drive to the IML; because they act centrally, they produce broader autonomic suppression than alpha-1 blockers acting only at peripheral vascular smooth muscle -- including sedation, dry mouth, and centrally mediated bradycardia not seen with peripheral alpha-1 blockade.
• B) Metoprolol and bisoprolol reduce RVLM tonic drive by blocking beta-1 adrenergic receptors within the RVLM vasomotor center, reducing the cAMP-dependent firing of sympathetic preganglionic neurons -- this central beta-1 blockade accounts for the disproportionately large blood pressure reduction with these drugs compared to their peripheral cardiac effects, and explains their particular efficacy in high-renin hypertension.
• C) Verapamil and diltiazem reduce RVLM tonic drive by blocking L-type calcium channels in RVLM vasomotor neurons, reducing spontaneous action potential generation and tonic excitatory output to sympathetic preganglionic neurons; their central vasomotor center action accounts for the orthostatic hypotension and sedation that differentiate them from dihydropyridine calcium channel blockers that act exclusively at peripheral vascular smooth muscle.
• D) Clonidine and methyldopa act as alpha-2 adrenergic agonists within brainstem nuclei -- clonidine directly activates alpha-2 receptors (and imidazoline I1 receptors) in the NTS and RVLM circuit, reducing tonic sympathetic preganglionic outflow and thereby lowering peripheral vascular resistance and heart rate; methyldopa is converted to alpha-methylnorepinephrine in the CNS, which acts as an alpha-2 agonist at these same sites; central action produces broader autonomic effects than peripheral agents -- including sedation (locus coeruleus alpha-2 activation) and dry mouth -- because central sympathetic drive is globally reduced rather than single-effector targeted.
• E) Hydralazine and minoxidil reduce RVLM tonic drive by activating soluble guanylate cyclase within RVLM vasomotor neurons, increasing cGMP and reducing neuronal excitability through hyperpolarizing potassium channel activation; their central mechanism of action accounts for the reflex tachycardia they produce, which paradoxically reflects reduced central baroreflex suppression of the sympathetic drive to the sinoatrial node.

4. Autonomic ganglia perform active signal integration rather than simply relaying signals. Which of the following most accurately describes the fast excitatory postsynaptic potential (fast EPSP) at an autonomic ganglion, the receptor mediating it, and why this receptor is pharmacologically distinct from the superficially similar receptor at the neuromuscular junction?

• A) The fast EPSP at autonomic ganglia is mediated by nicotinic NN receptors identical in subunit composition to the neuromuscular junction NM receptor -- both contain alpha1, beta1, delta, and epsilon subunits; because NN and NM receptors share the same subunit composition, neuromuscular blocking agents such as vecuronium necessarily also block ganglionic transmission at clinical doses, producing the combined sympatholytic and parasympatholytic profile characteristic of ganglionic blockade.
• B) The fast EPSP at autonomic ganglia is mediated by GABA-A receptors activated by inhibitory interneurons within the ganglion -- GABAergic interneurons constitute the primary excitatory drive in autonomic ganglia because GABA-A receptor activation is depolarizing (not hyperpolarizing) in ganglionic neurons due to their high intracellular chloride concentration relative to extracellular.
• C) The fast EPSP at autonomic ganglia is mediated by nicotinic NN receptors -- pentameric ligand-gated Na+/K+ ion channels composed predominantly of alpha3 and beta4 subunits -- whose pharmacological blockade by hexamethonium and trimethaphan interrupts ganglionic transmission in both sympathetic and parasympathetic ganglia simultaneously; NN receptors are pharmacologically distinct from NM receptors at the neuromuscular junction (composed of alpha1, beta1, delta, and epsilon/gamma subunits), and this subunit composition difference is the basis for the clinical selectivity of neuromuscular blockers (rocuronium, vecuronium) for NM receptors without ganglionic blockade.
• D) The fast EPSP at autonomic ganglia is mediated by NMDA-type glutamate receptors activated by glutamate co-released with acetylcholine from preganglionic terminals -- the NMDA receptor requires prior nicotinic depolarization to relieve the resting magnesium block before ganglionic activation can proceed; this two-stage activation mechanism explains why ketamine, an NMDA antagonist, produces autonomic ganglionic blockade at subanesthetic doses in clinical practice.
• E) The fast EPSP at autonomic ganglia is mediated by alpha-1 adrenergic receptors activated by norepinephrine released from the preganglionic terminal alongside acetylcholine through cotransmission -- the alpha-1 Gq-mediated slow EPSP lasting 10-30 seconds provides the principal excitatory drive to postganglionic neurons and is blocked by prazosin, explaining why prazosin produces both peripheral vasodilation and ganglionic blockade.

5. Visceral referred pain -- the perception of organ-originating pain as arising from remote somatic structures -- is explained by a specific neuroanatomical principle. Which of the following correctly identifies this principle and its clinically relevant pharmacological implication?

• A) Visceral afferents travel with parasympathetic nerves and converge on thalamic relay nuclei alongside somatic sensory afferents from remote body regions -- the thalamic convergence produces mismapping of visceral pain to somatic territories, and thalamic neuroplasticity explains the chronification of referred pain; thalamic stimulation is the target of deep brain stimulation for chronic visceral pain syndromes including refractory angina.
• B) Visceral afferents travel with sympathetic nerves through the dorsal roots and converge on the same dorsal horn neurons as cutaneous somatic afferents from anatomically distant regions sharing the same spinal segments -- cardiac ischemia originating at T1-T5 visceral levels is referred to the chest, jaw, and left arm whose somatic afferents enter T1-T5; this convergence-projection mechanism explains why nitrates, which relieve cardiac ischemia by reducing myocardial oxygen demand, simultaneously relieve the left arm pain of angina even though the arm itself is not ischemic.
• C) Referred pain arises from ephaptic (electrical cross-talk) transmission between visceral C-fibers and adjacent somatic A-delta fibers within the sympathetic trunk -- the spontaneous depolarization of ischemic visceral C-fibers produces cross-activation of somatic fibers at the same trunk level, generating the somatic pain pattern; drugs that stabilize the neuronal membrane (lidocaine, mexiletine) at the sympathetic trunk level block referred pain without affecting the underlying visceral pathology.
• D) Visceral pain is transmitted via the spinothalamic tract only after relay through the nucleus tractus solitarius, which projects diffusely to multiple somatosensory cortex areas -- the imprecision of visceral pain localization reflects the diffuse NTS projection rather than spinal cord convergence; NTS inhibition by opioids at the brainstem level accounts for the referred pain relief produced by systemic opioid administration in visceral pain syndromes.
• E) Referred pain from pelvic viscera follows sympathetic afferents through the lumbar roots to produce pain referred to the anterior thigh and inguinal region -- bladder pain is therefore referred to the right iliac fossa and uterine pain is referred to the medial thigh; this lumbar sympathetic pathway explains why lumbar sympathetic blockade with local anesthetics is the treatment of choice for acute pelvic visceral pain including labor pain.